Literature DB >> 27976415

Up-Regulation of Follistatin-Like 1 By the Androgen Receptor and Melanoma Antigen-A11 in Prostate Cancer.

Shifeng Su1,2, Amanda B Parris1, Gail Grossman1, James L Mohler3,4,5,6, Zengjun Wang2, Elizabeth M Wilson1,3,7.   

Abstract

BACKGROUND: High affinity androgen binding to the androgen receptor (AR) activates genes required for male sex differentiation and promotes the development and progression of prostate cancer. Human AR transcriptional activity involves interactions with coregulatory proteins that include primate-specific melanoma antigen-A11 (MAGE-A11), a coactivator that increases AR transcriptional activity during prostate cancer progression to castration-resistant/recurrent prostate cancer (CRPC).
METHODS: Microarray analysis and quantitative RT-PCR were performed to identify androgen-regulated MAGE-A11-dependent genes in LAPC-4 prostate cancer cells after lentivirus shRNA knockdown of MAGE-A11. Chromatin immunoprecipitation was used to assess androgen-dependent AR recruitment, and immunocytochemistry to localize an androgen-dependent protein in prostate cancer cells and tissue and in the CWR22 human prostate cancer xenograft.
RESULTS: Microarray analysis of androgen-treated LAPC-4 prostate cancer cells indicated follistatin-like 1 (FSTL1) is up-regulated by MAGE-A11. Androgen-dependent up-regulation of FSTL1 was inhibited in LAPC-4 cells by lentivirus shRNA knockdown of AR or MAGE-A11. Chromatin immunoprecipitation demonstrated AR recruitment to intron 10 of the FSTL1 gene that contains a classical consensus androgen response element. Increased levels of FSTL1 protein in LAPC-4 cells correlated with higher levels of MAGE-A11 relative to other prostate cancer cells. FSTL1 mRNA levels increased in CRPC and castration-recurrent CWR22 xenografts in association with predominantly nuclear FSTL1. Increased nuclear localization of FSTL1 in prostate cancer was suggested by predominantly cytoplasmic FSTL1 in benign prostate epithelial cells and predominantly nuclear FSTL1 in epithelial cells in CRPC tissue and the castration-recurrent CWR22 xenograft. AR expression studies showed nuclear colocalization of AR and endogenous FSTL1 in response to androgen.
CONCLUSION: AR and MAGE-A11 cooperate in the up-regulation of FSTL1 to promote growth and progression of CRPC. Prostate 77:505-516, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  FSTL1; MAGE-A11; androgen receptor; follistatin-like 1; melanoma antigen-A11; prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 27976415     DOI: 10.1002/pros.23288

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

1.  FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway.

Authors:  Ya-Kun Liu; Ya-Jing Jia; Shi-Hao Liu; Jing Ma
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-03       Impact factor: 3.333

2.  FSTL1 promotes growth and metastasis in gastric cancer by activating AKT related pathway and predicts poor survival.

Authors:  Mengjie Wu; Yongfeng Ding; Nan Wu; Junjie Jiang; Yingying Huang; Fanyu Zhang; Haiyong Wang; Quan Zhou; Yan Yang; Wei Zhuo; Lisong Teng
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

3.  Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma.

Authors:  Yan Liu; Xiaojie Tan; Wenbin Liu; Xi Chen; Xiaomei Hou; Dan Shen; Yibo Ding; Jianhua Yin; Ling Wang; Hongwei Zhang; Yongwei Yu; Jianguo Hou; Timothy C Thompson; Guangwen Cao
Journal:  Chin J Cancer       Date:  2018-01-22

Review 4.  Follistatin-like 1 in development and human diseases.

Authors:  Andrea Mattiotti; Stuti Prakash; Phil Barnett; Maurice J B van den Hoff
Journal:  Cell Mol Life Sci       Date:  2018-03-29       Impact factor: 9.261

5.  Deficiency of Follistatin-Like Protein 1 Accelerates the Growth of Breast Cancer Cells at Lung Metastatic Sites.

Authors:  Ying Zhang; Xiaozhou Xu; Ying Yang; Jie Ma; Lulu Wang; Xiangzhi Meng; Bing Chen; Ling Qin; Tao Lu; Yan Gao
Journal:  J Breast Cancer       Date:  2018-09-20       Impact factor: 3.588

6.  MAGE-A11 Expression Predicts Patient Prognosis in Head and Neck Squamous Cell Carcinoma.

Authors:  Shiheng Jia; Minghui Zhang; Yanshu Li; Lan Zhang; Wei Dai
Journal:  Cancer Manag Res       Date:  2020-02-26       Impact factor: 3.989

7.  Chronic IL-1 Exposed AR+ PCa Cell Lines Show Conserved Loss of IL-1 Sensitivity and Evolve Both Conserved and Unique Differential Gene Expression Profiles.

Authors:  Shayna E Thomas-Jardin; Mohammed S Kanchwala; Haley Dahl; Vivian Liu; Rohan Ahuja; Reshma Soundharrajan; Nicole Roos; Sydney Diep; Amrit Sandhu; Chao Xing; Nikki A Delk
Journal:  J Cell Signal       Date:  2021-12

8.  Determination of follistatin-like protein 1 expression in colorectal cancer and its association with clinical outcomes.

Authors:  Yujie Zhao; Qingjian Ou; Yuxiang Deng; Jianhong Peng; Cong Li; Jibin Li; Qian Zhao; Miaozhen Qiu; Desen Wan; Yujing Fang; Zhizhong Pan
Journal:  Ann Transl Med       Date:  2019-11

9.  Effects of FSTL1 on the proliferation and motility of breast cancer cells and vascular endothelial cells.

Authors:  Yang Yang; Tianhao Mu; Te Li; Songbo Xie; Jun Zhou; Min Liu; Dengwen Li
Journal:  Thorac Cancer       Date:  2017-08-30       Impact factor: 3.500

Review 10.  Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells.

Authors:  Takeshi Namekawa; Kazuhiro Ikeda; Kuniko Horie-Inoue; Satoshi Inoue
Journal:  Cells       Date:  2019-01-20       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.